drugset

drugset / Trial / NCT06812325

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325 ↗

Phase 3 Active not recruiting 320 enrolled Viridian Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Timeline

Start: 2025-02-03
Primary completion: 2026-04-22
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VRDN-003	Monoclonal antibody	—	Subcutaneous

Indications